Personal Care & OTC Dashboard.
A reference hub on Japan's listed personal-care and OTC-health franchises.
Five active names inside one TSE bucket, five economic archetypes, and a single sector law: the market capitalises only the compounding of organic earnings per share in local currency. Kao and Lion are clean recoveries — real, but already in the price. Unicharm is an emerging cyclical whose growth premium has been correctly de-rated away. Rohto is the one structural mispricing — a dermo-cosmetic compounder filed under OTC pharma — but the discount has partly closed into a 24 June activist meeting, and the decisive product margin is not disclosed. Kobayashi's earnings are recovering on a capital base that no longer turns, and the price holds both. The consolidated sector multiple is the wrong tool across all five.
The five active names sit inside the same TSE bucket but no longer trade on the same logic. Kao Corporation (4452.T), Unicharm Corporation (8113.T), Lion Corporation (4912.T), Rohto Pharmaceutical (4527.T) and Kobayashi Pharmaceutical (4967.T) span five economic archetypes — diversified FMCG platform, emerging absorbent-hygiene champion, mature domestic operator, self-care brand-led compounder, sub-scale niche specialist. A sixth name, Mandom (4917.T), left the universe through a tender offer in May 2026 and is retained for historical reference only. Forward earnings multiples run from roughly 16x at Rohto to 30x and above at Kobayashi on a depressed near-year base. The dispersion is itself the first read.
The decade settled one thing for this bucket. The market capitalises a single variable durably — the compounding of organic earnings per share in local currency, proven through pricing power in an inflationary regime and through quiet compounding across cycles. Everything else — a niche narrative premium, an excess emerging-growth premium, a currency-translation tailwind, a macro re-rating, a P/E inflated on a depressed denominator — is transitory and mean-reverting. The collective quality premium that once let the sector trade as a homogeneous block has gone, replaced by discrimination on the decomposition of returns: earnings-led against multiple-led.
Two structural facts run across every name. The first is a net-cash balance sheet that floors valuation everywhere and dilutes the consolidated return on capital everywhere — so the operating return reconstructed clear of non-operating capital is systematically higher than the reported figure, and the market anchors on the lower one. The second is the TSE governance reform, which has turned dormant balance sheets into a live question and put two of the five names under named activist pressure. Neither fact is a thesis on its own; together they explain why every debate in the bucket is about recognition and capital allocation, not about whether the engine works.
What follows sits in three layers. The economic engine and the cross-name inputs describe what is shared across the five. The archetype map and the names section sort them. The mispriced variables and the structural watchlist track what each consensus is reading wrong and what would force a reframing.
The single most decisive structural variable across the bucket is the gap between the operating return on capital and the consolidated return the market reads. Every name carries non-operating capital that sits in the denominator earning nothing — Kao's chemical arm and net cash, Unicharm's ¥161bn financial portfolio, Lion's and Kobayashi's net cash, Rohto's fortress spent into goodwill. Strip it out and three of the platforms show operating returns far above the cost of capital: Kao's consumer core near 16.5%, Rohto's organic engine near 14.9%, Unicharm's operating base near 13.7%, each well above a ~6–7% cost of capital, against consolidated returns of 9.2%, 9.7% and 7.7%. The consolidated line understates the engine, uniformly.
The second variable is segment and regional dispersion inside the consolidated margin. Kao averages a 19.1% Fabric & Home oligopoly, a 4.0% cosmetics business and a 7.4% chemical arm under one 9.7% line. Lion carries an 8.5% Consumer Products core against a 4.3% overseas business, within which South-East Asia runs 6.0% and China 1.5%. Rohto publishes Japan at 13.1%, Asia at 12.0%, the Americas at 7.9% and Europe at 4.2%. Kobayashi earns 11.8% domestically against 1.7% internationally. A single consolidated margin is the weighted average of economically unlike businesses; once dispersion inside an operator is wide, the consolidated multiple stops being the right tool and a sum-of-the-parts is required.
Pricing power is the third variable, and it is proven only under inflation. One name passed the test — Rohto held its margin, 14.5% to 14.8%, through the 2022–2023 oleochemical shock, while Kao collapsed from 10.1% to 3.9% and Lion compressed from 8.5% to 5.1%. Kao's Fabric & Home is a second, narrower pocket, raising price and volume together for roughly thirty months. Everywhere else the pricing power claimed in calm conditions is a projection rather than a fact: Unicharm takes price in China, Kobayashi's gross margin has eroded from 57.4% to 51.1%, and Lion's household book outside oral care has none.
The critical cost differs by name but is never a simple raw-material story. For Kao and Lion it is the oleochemical spread, lagged twelve to twenty-four months, which manufactures cyclical margin troughs the market regularly misreads as structural. For Unicharm it is competitive and promotional intensity in China and South-East Asia, discretionary going in and sticky coming out. For Kobayashi it is the under-absorption of the fixed costs of an oversized plant. For Rohto it is the J-GAAP amortisation of acquisition goodwill. The bucket's real risks are capital and confidence, not inputs.
The first cross-name input is the yen, which cuts two ways here. For the decade to 2024 a weak yen flattered emerging revenue translated back into reporting currency — Unicharm's record ¥989bn FY2024 top line masked an Asian engine that had already begun to stall. The reversion now runs the other way: a stronger yen is a translation headwind on the emerging names, Unicharm's Asia and Rohto's ASEAN skincare, and removes the currency illusion that inflated the FY2021–2023 top line. The modelling discipline is to re-state earnings in local currency before crediting growth, taking mid-cycle USD/JPY near 140–145 with the downside sensitivity at 130–135.
The second input is the oleochemical cycle. Natural fats, palm and surfactant derivatives move on a twelve-to-twenty-four-month lag, so the input shock lands before the price response catches up. The cycle drove the FY2023 trough and the FY2024–2025 recovery in both Kao and Lion, and it is the single factor the market most reliably misprices as structural at the bottom — Lion's margin was sold at its 5.1% trough and then recovered to 8.6%. Rohto is largely insulated by pricing power; Kao is doubly exposed because its captive chemical arm sits directly on the spread, compressing chemical operating profit by ¥5.5bn in FY2025. The discipline is a stress test of margin under a +30% input shock and a reading of how each name behaved through 2022–2023.
The third input is the TSE reform and the activism it has produced. The Tokyo Stock Exchange's pressure on capital efficiency has turned every dormant balance sheet in the bucket into a live question and produced named campaigns at two of the five: Asset Value Investors and Longchamp at Rohto, with a contested meeting dated 24 June 2026, and Oasis above 10% of Kobayashi with a derivative action on file. The right treatment is to value each name ex-activist-premium and hold the floor as optionality, never as a base. The same reform is the common re-rating lever — mobilisation of dormant capital — that the price holds least across the bucket, and the reason a bull case exists on most of these names at all.
| Archetype | Name | Read |
|---|---|---|
|
A · Diversified FMCG platform
Consumer core, captive oleochemicals
|
Kao Corporation 4452.T | A 9.7% consolidated margin averages a 19.1% Fabric & Home oligopoly, a 4.0% cosmetics business just back in profit and a 7.4% chemical arm on the input cycle. The inherited conglomerate-discount thesis does not survive the certified segment data — once chemistry is priced at 7.4% rather than the assumed near-zero, the sum of the parts lands on the ¥2,652bn market cap. Four-fifths of the FY2025 profit improvement came from one cyclical, China-dependent segment, so the recovery is real but narrow and already in the price; the −0.8% share reaction to a +24% Q1 beat is the market confirming it. Weighted fair value −5.7%. Composite quality 16.0 / 25. |
|
B · Emerging absorbent hygiene
Growth premium de-rated, operating engine intact
|
Unicharm Corporation 8113.T | The consolidated 10.8% margin describes a company that does not exist — a structural Rest-of-World engine, a defensive Japan base and an Asia at 41% of revenue losing a Chinese price war, down −12.1% in yen and dragging group operating profit −24% through a ~4.8x regional lever. The de-rating from a 5.94x price-to-book in 2020 to 1.94x is the rational end of an emerging-growth premium that was never earned; the reverse DCF confirms the price encodes a flat 9–10% normalised return on equity, not an overshoot. The operating return ex-portfolio is near 13.7% against a 7.7% consolidated figure. Weighted fair value +1.9%, the least negative in the bucket. Composite quality 15.5 / 25. |
|
C · Mature domestic operator
Margin recoverer, dormant balance sheet
|
Lion Corporation 4912.T | Revenue grew 11% in a decade; the entire move in earnings came from a margin that swung from 4.3% to a 12.4% COVID peak to a 5.1% trough and back to 8.6%. The recovery is domestic and specific — the Consumer Products core moved from 6.5% to 8.5% on profit-structure reform and accepted oral-care premiumisation — carried alongside an overseas business at half the domestic margin, within which South-East Asia converges while China destroys value. The patrimonial cushion the inherited thesis leaned on has thinned: net cash fell from ¥85bn to ¥42.9bn as the Vietnamese acquisition consumed roughly half of it. Weighted fair value −4.0%. Composite quality 16.0 / 25. |
|
D · Self-care brand-led
Dermo-cosmetic compounder filed as OTC
|
Rohto Pharmaceutical 4527.T | The market files Rohto at the floor of its decade — roughly 16x earnings, an OTC-pharmaceutical multiple — when 57% of revenue is skincare and the organic return on capital clean of acquisition goodwill is near 14.9%. The catch is disclosure: profit is published only by geography, so the dermo-cosmetic margin that would justify the re-rating can only be inferred, not read. The fortress balance sheet has been spent into goodwill across 46 consolidated subsidiaries, and the one un-priced upside — a 24 June activist contest — has already drawn an ~8% rally into the meeting. Highest quality in the bucket at 16.5 / 25, on the most depressed multiple; weighted fair value −1.3%. |
|
E · Sub-scale niche specialist
Concentrated-shock turnaround, stranded capital
|
Kobayashi Pharmaceutical 4967.T | The earnings are recovering — quarterly net income turned positive in Q1 FY2026 and consensus has EPS near-trebling toward the pre-scandal peak — but they are set against a capital base that tripled. The fixed asset turnover that read 8.3x a decade ago now reads 2.46x as the beni-koji shock erased the supplements category and left a new plant idle; the same normalised profit divided by three times the capital caps return on capital at 1.7%. The price holds both the earnings coming back and the capital being worth what it was, and a 2.5x asset turnover cannot deliver both. Weighted fair value −27%, the only materially negative read; documented short bias, no datable catalyst. Composite quality 11.5 / 25, the one name that decouples. |
Underneath a 9.7% consolidated margin sits a 19.1% Fabric & Home oligopoly taking share while raising price — the value anchor and the floor — carrying a cosmetics business just back to a 4.0% margin and a chemical arm at 7.4% on the oleochemical cycle. The inherited conglomerate discount does not survive the segment data: priced part by part, the sum reconstructs onto the ¥2,652bn market cap.
Four-fifths of the FY2025 profit improvement came from one cyclical, China-dependent segment. The recovery is real, well-executed and largely in the price — the −0.8% reaction to a +24% Q1 beat is the tell. Weighted fair value −5.7%; the un-priced upside is a cosmetics margin lift toward prestige peers or a mobilisation of the dormant balance sheet, neither signalled. Watchlist, modest negative bias, sizing zero.
The consolidated 10.8% margin is the weighted average of a structural Rest-of-World engine, a defensive Japan base and a contested Asia at 41% of revenue that fell −12.1% in yen and pulled group operating profit −24% through a ~4.8x regional lever. The de-rating to 1.94x book is the rational end of a growth premium that was never earned, not an overshoot — the reverse DCF reads a flat 9–10% normalised return on equity.
The operating return ex-portfolio is near 13.7% against a 7.7% consolidated figure diluted by ¥161bn of dormant financial portfolio. Weighted fair value +1.9%, the least negative in the bucket, on a wide but bidirectional cone of −25% to +36%. The binary — Asian margin cyclical or a permanent step-down — resolves on the FY December 2026 print, not through more modelling. Watchlist, sizing zero.
A domestic margin recoverer on a fortress balance sheet: the Consumer Products core moved from a 6.5% to an 8.5% margin on profit-structure reform and accepted oral-care premiumisation, carried alongside an overseas business at 4.3% — within which South-East Asia (6.0%, growing fast) converges while China (1.5%) destroys value. The recovery is real, domestically driven and largely in the price at ~17.3x forward.
The patrimonial cushion the inherited thesis leaned on has thinned — net cash fell from ¥85bn to ¥42.9bn as the Vietnamese acquisition of Merap consumed roughly half of it, the first live evidence of how the capital gets spent. Weighted fair value −4.0%; the bias is long but conditional on the domestic margin proving structural through 9% or a quantified capital-return lift, neither signalled. Watchlist, sizing zero.
The most depressed multiple in the bucket on the highest quality score — roughly 16x earnings for a business that is 57% skincare with an organic return on capital near 14.9%. The disclosure is the catch: profit is published only by geography, so the dermo-cosmetic margin that would carry the re-rating sits inside a 13.1% Japan segment and can only be inferred. The fortress balance sheet has been spent into goodwill across 46 subsidiaries, pulling consolidated return on capital from 12.7% to 9.7%.
The one un-priced lever is the 24 June activist contest — AVI on the chairman, Longchamp on the cost of capital — and the discount has partly closed, the share up ~8% into the meeting to ¥2,540. Weighted fair value −1.3% after the rally; the long bias is documented but event-gated on the meeting and the first Asia margin print. The only modellable dislocation in the bucket. Watchlist, sizing zero.
The earnings are recovering — Q1 FY2026 turned positive, consensus has EPS near-trebling toward the pre-scandal peak — but they are set against a capital base that tripled at the top of the cycle. The fixed asset turnover fell from 8.3x to 2.46x as the beni-koji shock erased the supplements category and left a new plant idle; the same normalised profit divided by three times the capital caps return on capital at 1.7%.
At ¥5,627 the price carries a P/B of 2.0x implying a ~10% return on equity the normalised model does not support — it holds both the earnings coming back and the capital being worth what it was. Weighted fair value −27%, the only materially negative read in the bucket. Documented short bias but not cleanly actionable: the activist floor, the net-cash fortress and the EV/EBITDA anchor leave no datable de-rating catalyst. Watchlist, sizing zero.
| Metric | Who it tests | What would change the read |
|---|---|---|
| Cosmetics segment operating profit | Kao · 4452.T | Two consecutive prints back below ~¥6bn annualised confirm a Chinese relapse and pull fair value toward ¥4,000–4,300. A margin durably through 8% toward prestige peers, with consolidated volume positive ex-price, confirms the structural reading. |
| Asia / Personal Care core operating margin | Unicharm · 8113.T | At the FY December 2026 print, below 10% with Asian volume positive confirms the structural step-down and pulls fair value toward ¥662. Above 12% confirms the cyclical reading and reopens the path toward ¥1,100–1,200. |
| Consumer Products core operating margin | Lion · 4912.T | Holding at or above 8.5% in a stable input regime across the FY2026 and 9M FY2027 prints confirms the structural step. Below 8% over two consecutive prints confirms a cyclical rebound already priced and pulls fair value toward ¥1,125. |
| Activist meeting outcome and product-margin disclosure | Rohto · 4527.T | A buyback beyond the ¥5.0bn template or a dividend-governance reform out of the 24 June meeting confirms capital mobilisation; a product-margin disaggregation showing skincare durably above 18% validates the dermo-cosmetic premium. Absent both, the geographic grain holds and the re-rating stays an inference. |
| Consolidated return on capital and Eu Yan Sang goodwill | Rohto · 4527.T | Consolidated return on capital reconverging toward ≥11% by March 2028 confirms the roll-up is accretive. A return stuck below 10% with an impairment on the ¥34.2bn goodwill converts the bear from a timing disappointment into permanent capital destruction. |
| Fixed asset turnover and beni-koji liability bound | Kobayashi · 4967.T | At the FY2026 accounts (~February 2027), a fixed asset turnover durably above 4x with the liability bound certified resets the asymmetry toward neutral. Below 4x with an impairment test confirms permanent stranded capital and pulls fair value toward ¥2,600–2,900. |
| Capital mobilisation under TSE pressure | Cross-bucket | A quantified multi-year capital-return policy at any of the four net-cash names — accelerated buyback, raised payout, or portfolio disposal — is the common un-priced re-rating lever. Continued balance-sheet inertia confirms the dormant-capital discount across the bucket. |
The framework rests on one sector law — that the market capitalises only the compounding of organic earnings per share in local currency, and that the collective quality premium of the pre-2020 era is gone for good. If the Tokyo market re-rates defensive consumer cash generators back toward their historical means on a sustained move in real rates, the "recovery already in the price" read on Kao and Lion is wrong and the inflated five-year multiple averages become directional benchmarks again. This is not the base case, but it is the cleanest single invalidation of the bucket's central logic.
The second invalidation runs through the two structural debates. If Unicharm's Asian margin recovers through 12% rather than settling at a permanently lower step, the de-rating is excessive and the cyclical reading reopens a path well above spot. If Rohto's disclosure changes — a product-margin disaggregation putting skincare durably above 18% — the dermo-cosmetic archetype is confirmed and the re-rating the price refuses to pay becomes underwritable. Both are observable on the published calendar; neither is signalled today. The symmetrical risk is allocation: at four of the five names the dormant balance sheet could fund a value-destructive acquisition as easily as a capital return, and that — not an operating miss — is the way a permanent loss would arrive.
This dashboard is the reference document for sub-industry 03b. Single-name memos and recurring publications touching this universe are listed below. Mandom (4917.T) left the universe through a CVC tender offer in May 2026 and carries no memo.
- 4452.T Kao Corporation Published
- 8113.T Unicharm Corporation Published
- 4912.T Lion Corporation Published
- 4527.T Rohto Pharmaceutical Published
- 4967.T Kobayashi Pharmaceutical Published
- — First issue forthcoming
- — No issue to date
The information provided on this website is for informational and educational purposes only and should not be construed as financial, investment, legal, or tax advice. All content reflects the personal opinions, interpretations, and analyses of the author at the time of writing and is subject to change without notice. Nothing contained herein constitutes, or should be interpreted as, a recommendation, solicitation, or offer to buy or sell any securities, financial instruments, or other investment products. The author is not a licensed financial advisor, broker, or investment professional. Any references to specific assets, markets, or strategies are illustrative in nature and do not constitute personalized investment advice. Investing in financial markets involves risk, including the potential loss of capital. Past performance is not indicative of future results. Readers are solely responsible for their own investment decisions and should conduct their own independent research and due diligence before making any financial commitments. You are strongly encouraged to consult with a qualified financial advisor, legal professional, or other relevant specialist before making any investment or financial decisions. By accessing and using this blog, you agree that the author shall not be held liable for any direct or indirect losses, damages, or consequences arising from the use of, or reliance on, the information presented herein. All content is provided "as is" without any warranties of completeness, accuracy, or reliability.